Drug Information

Drug (ID: DG00777) and It's Reported Resistant Information

• Name: Moclobemide
• Synonyms: Moclobemide; 71320-77-9; Aurorix; Moclobemid; Manerix; Moclamine; 4-chloro-N-(2-morpholinoethyl)benzamide; Moclaime; Moclobemidum; Moclamide; Moclobemida; Moclobemidum [INN-Latin]; Moclobemida [INN-Spanish]; p-Chloro-N-(2-morpholinoethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; Ro 11-1163; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; Moclobemide (Ro 111163); GNF-PF-695; 4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide; UNII-PJ0Y7AZB63; Ro 11-1163/000; Ro111163; BENZAMIDE, 4-CHLORO-N-(2-(4-MORPHOLINYL)ETHYL)-; Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-; PJ0Y7AZB63; CHEMBL86304; MLS000070549; CHEBI:83531; MFCD00865388; NCGC00027930-02; NCGC00027930-04; SMR000012114; DSSTox_CID_20554; DSSTox_RID_79506; DSSTox_GSID_40554; Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Auromid; Aurorix (TN); CAS-71320-77-9; Ro-11-1163; HSDB 7180; SR-01000357772; CBMicro_048319; Moclobemide (USAN/INN); BRN 0530974; Moclobemide- Bio-X; Moclamine (Salt/Mix); Opera_ID_225; Oprea1_256739; Oprea1_270122; SCHEMBL49708; MLS000759438; MLS001240195; MLS001424077; GTPL7428; BENZAMIDE,4-CHLORO-N-[2-(4-MORPHOLINYL)ETHYL]-; DTXSID9040554; BDBM15613; AOB5012; HMS2051A16; HMS2096G07; HMS2232B20; HMS3262F09; HMS3371A01; HMS3393A16; HMS3657K05; HMS3713G07; HMS3885A15; AMY32534; BCP15783; HY-B0534; Moclobemide 1.0 mg/ml in Methanol; Tox21_110971; Tox21_113614; Tox21_500824; s3212; STK222240; ZINC19606670; AKOS003270184; Moclobemide, >=98% (HPLC), solid; Tox21_110971_1; CCG-100879; DB01171; LP00824; MCULE-5300106938; NC00129; SDCCGSBI-0048213.P003; NCGC00027930-03; NCGC00027930-05; NCGC00027930-07; NCGC00027930-16; NCGC00261509-01; AC-12467; BM164599; H223; p-chloro-N-(2-morpholinoethyl)-benzamide; BIM-0048213.P001; Ro-111163000; FT-0618228; M2733; SW197509-3; Ro-11-1163/000; D02561; AB00400932_12; 320M779; A837152; Q421934; 4-chloro-N-(2-morpholinoethyl)benzamide;Moclobemide; SR-01000357772-1; SR-01000357772-4; Z32409934; Ro11-1163; Ro 11-1163; Ro111163; Ro-111163; Ro 111163; 108375-13-9; MCL
• Indication:
  In total 2 Indication(s)
  Depression [ICD-11: 6A70]; Approved; [1]
  Skin imperfections [ICD-11: EK71]; Approved; [1]
• Target: Monoamine oxidase (MAO); NOUNIPROTAC; [1]
• Target: Monoamine oxidase type A (MAO-A); AOFA_HUMAN; [1]
• Formula: C13H17ClN2O2
• IsoSMILES: C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
• InChI: 1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
• InChIKey: YHXISWVBGDMDLQ-UHFFFAOYSA-N
• PubChem CID: 4235
• ChEBI ID: CHEBI:83531
• TTD Drug ID: D01ZSO
• VARIDT ID: DR00838
• INTEDE ID: DR1103
• DrugBank ID: DB01171

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Prostate cancer [ICD-11: 2C82]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Monoamine oxidase A (MAOA) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Prostate cancer [ICD-11: 2C82.0]
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Monoamine oxidase A (MAOA) may promote tumor burden and drug/castration resistance in PCa. A positive association will pave the way for MAOA inhibitors such as moclobemide for PCa therapy. Association of key molecules of oncogenesis and metastasis with MAOA suggests that MAOA inhibitors such as moclobemide might be effective in the management of PCa.

References

• Ref 1: Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer .Curr Ther Res Clin Exp. 2020 Oct 28;93:100610. doi: 10.1016/j.curtheres.2020.100610. eCollection 2020. 10.1016/j.curtheres.2020.100610